Inloggad som:
avslutad_DESTINY-B12
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_DESTINY-B12
En öppen, multinationell multicenterstudie i fas 3b/4 av trastuzumab deruxtecan hos patientermed eller utan hjärnmetastaser vid baslinje med tidigare behandlad avancerad/metastaseradHER2-positiv bröstcancer (DESTINY- Breast12)
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
PLACEHOLDER
Mer information om studien för vårdgivare
Participant must be ≥ 18 years at the time of screening. Pathologically documented breast cancer that:
(a) Is unresectable/advanced or metastatic, and
(b) Has confirmed HER2-positive status
Participant must have either:
(a) No evidence of BM, or
(b) Untreated BM on screening contrast brain MRI / CT
1 Known or suspected LMD. If LMD has been reported radiographically on baseline MRI
but is not suspected clinically by the investigator, the participant must be free of
neurological symptoms of LMD1
2 Prior exposure to tucatinib treatment
Behandling
Fas 3
Ej tillämpbar
Företag
Studien ändrades senast av: studysonia (2023-08-28)